Cargando…
HER2/neu-directed therapy for biliary tract cancer
BACKGROUND: Biliary cancers are highly aggressive tumors that are often diagnosed an advanced disease stage and have a poor outcome with systemic therapy. Recent efforts towards molecular characterization have identified a subset of biliary patients that have HER2/neu amplification or mutation. HER2...
Autores principales: | Javle, Milind, Churi, Chaitanya, Kang, HyunSeon C., Shroff, Rachna, Janku, Filip, Surapaneni, Rakesh, Zuo, Mingxin, Barrera, Christian, Alshamsi, Humaid, Krishnan, Sunil, Mishra, Lopa, Wolff, Robert A., Kaseb, Ahmed O., Thomas, Melanie B., Siegel, Abby B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469402/ https://www.ncbi.nlm.nih.gov/pubmed/26022204 http://dx.doi.org/10.1186/s13045-015-0155-z |
Ejemplares similares
-
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014) -
Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling
por: Javle, Milind, et al.
Publicado: (2013) -
Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
por: Mizrahi, Jonathan D, et al.
Publicado: (2020) -
Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017) -
Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)